Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs

2015 ASCO Annual Meeting

29 May - 2 Jun 2015

Published: 1 Jun 2015

Views: 2268

Rating:

Save

Dr Richard Schilsky - University of Chicago, Chicago, USA

Dr Schilsky presents, at a press conference at ASCO 2015, the Targeted Agent and Profiling Utilization Registry (TAPUR).

It is the first ASCO-led clinical trial, which will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect "real-world" data on clinical outcomes to help learn the best uses of these drugs outside of indications.

Related Videos

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Latest in hormone sensitive prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof...

Latest in hormone sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof Heather Payne )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

The future of precision oncology

Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany

The future of precision oncology ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )

Molecular profiling in prostate cancer: key challenges for clinical...

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer